EUVIMEDEUVIMED entdecken
Open Access

Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States

Amneet Sandhu iD, Lisa A Kaltenbach, Karen Chiswell iD, Vijay Shimoga, Carmel Ashur iD, Abby Pribish iD, Gregg C Fonarow iD, Jonathan P Piccini iD, P Michael Ho iD, Paul D Varosy, Paul L Hess

Circulation: Cardiovascular Quality and Outcomes · 2023-12 · 16 (12)

DOI: 10.1161/circoutcomes.123.010062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2023-12. Verfasst von Amneet Sandhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiology, Denver VA Medical Center, Aurora, CO (A.S., P.M.H., P.D.V., P.L.H.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Among patients hospitalized for atrial fibrillation, the frequency of off-label direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and temporal trends in contemporary practice are unknown. METHODS: Using the Get With The Guidelines–Atrial Fibrillation registry, patients admitted from January 1, 2014, to March 31, 2020, and discharged on DOACs were stratified according to receipt of underdosing, overdosing, or recommended dosing. Factors associated with off-label dosing (defined as underdosing or overdosing) were identified using logistic regression. Median odds ratio (OR) and time-series analyses were used to assess hospital-level variation and temporal trends, respectively. RESULTS: Of 22 470 patients (70.1±12.1 years, 48.1% female, 82.5% White) prescribed a DOAC at discharge from hospitalization for atrial fibrillation (66% apixaban, 29% rivaroxaban, and 5% dabigatran), underdosing occurred among 2006 (8.9%), overdosing among 511 (2.3%), and recommended dosing among 19 953 (88.8%). The overall rate of off-label dosing was 11.2%. Patient-related factors associated with off-label dose included age (underdosing: OR, 1.06 per 1-year increase [95% CI, 1.06–1.07]; overdosing: OR, 1.07 per 1-year increase [95% CI, 1.06–1.09]), dialysis dependence (underdosing: OR, 5.50 [95% CI, 3.76–8.05]; overdosing: OR, 5.47 [95% CI, 2.74–10.88]), female sex (overdosing: OR, 0.79 [95% CI, 0.63–0.99]), and weight (overdosing: OR, 0.96 per 1-kg increase [95% CI, 0.95–1.00]). Across hospitals, the adjusted median OR for off-label DOAC dose was 1.45 (95% CI, 1.34–1.65; underdosing: OR, 1.52 [95% CI, 1.39–1.76]; overdosing: OR, 1.32 [95% CI, 1.20–1.84]), indicating significant hospital-level variation. Over the study period, recommended dosing significantly increased over time (81.9%–90.9%; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeHumansFemaleUnited StatesMaleOff-Label UseInpatientsRivaroxabanAnticoagulantsAdministration, Oral

Stichwörter der Autor:innen

anticoagulantsapixabanatrial fibrillationfactor XIregistries

Substanzen

RivaroxabanAnticoagulants

Autor:innen und Institutionen

  • Section of Cardiology, Denver VA Medical Center, Aurora, CO (A.S., P.M.H., P.D.V., P.L.H.).
  • Division of Cardiology, University of Colorado, Denver (A.S., C.A., A.P., P.M.H., P.D.V., P.L.H.).
  • Duke Clinical Research Institute, Durham, NC (L.A.K., K.C., J.P.P.).
  • University of Colorado School of Medicine, Aurora (V.S.).
  • Division of Cardiology, University of California Los Angeles (G.C.F.).
  • Duke University Hospital, Durham, NC (J.P.P.).

ORCID-Profile: Amneet Sandhu, Karen Chiswell, Carmel Ashur, Abby Pribish, Gregg C Fonarow, Jonathan P Piccini, P Michael Ho

Förderung

  • HSRD VA

Zitieren

APA

Sandhu, A., Kaltenbach, L. A., Chiswell, K., Shimoga, V., Ashur, C., Pribish, A., Fonarow, G. C., Piccini, J. P., Ho, P. M., Varosy, P. D., & Hess, P. L. (2023). Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States. Circulation: Cardiovascular Quality and Outcomes, 16(12). https://doi.org/10.1161/circoutcomes.123.010062

Vancouver

Sandhu A, Kaltenbach LA, Chiswell K, Shimoga V, Ashur C, Pribish A, et al. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States. Circulation: Cardiovascular Quality and Outcomes. 2023;16(12). doi:10.1161/circoutcomes.123.010062

BibTeX
@article{Sandhu2023,
  author = {Sandhu, Amneet and Kaltenbach, Lisa A and Chiswell, Karen and Shimoga, Vijay and Ashur, Carmel and Pribish, Abby and Fonarow, Gregg C and Piccini, Jonathan P and Ho, P Michael and Varosy, Paul D and Hess, Paul L},
  title = {Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States},
  journal = {Circulation: Cardiovascular Quality and Outcomes},
  year = {2023},
  volume = {16},
  number = {12},
  doi = {10.1161/circoutcomes.123.010062}
}
Kostenlos starten →